中国24家医疗机构COVID-19期间中成药使用回顾性研究
本研究收集中国14省24家医院在2020年四个时间段使用的前三种中成药,分析其应用规律与疫情的关系。结果显示清热类为早期主要类别,后期补益与活血化瘀类增多,且清热与非清热药使用率在风险区域、南北地区及不同性质医院间存在显著差异,风险区域为主要影响因素。
要点
- COVID-19早期以清热类中成药为主,后期转向补益与活血化瘀类。
- 清热与非清热药使用率在不同风险区域、南北地区及医院性质间有显著差异。
- 风险区域是中成药功效分布的主要影响因素。
核心结论
- 中成药一定程度参与了抗击COVID-19,其功效分布与风险区域、地区及医院性质相关,风险区域为主要影响因素。
研究设计与样本
- 回顾性研究,收集中国14省24家医院在2020年1月20-22日、2月16-18日、3月01-03日、4月01-03日四个时间段使用的前三种中成药,建立数据库并用SPSS 23.0进行χ2检验与相关性分析。
主要发现
- 2020年1月20-22日全国以清热类中成药为主,不同风险区域清热与非清热药使用率差异显著(p < 0.01)。
- 2020年2月16-18日中成药品种增多,以补益、活血化瘀和清热类为主,南北地区清热与非清热药使用率差异显著(p < 0.05)。
- 2020年3月01-03日全国以补益和活血化瘀类为主。
- 2020年4月01-03日全国仍以补益和活血化瘀类为主,不同风险区域清热与非清热药使用率差异显著(p < 0.01)。
临床怎么用
- 临床选用中成药时应结合疫情阶段、风险区域、南北地区及医院性质等因素综合考虑功效类别。
局限性
- 研究仅收集各医院使用的前三种中成药名称,未获取具体应用量,作者希望未来研究进一步收集全国医院中成药应用量以更完善反映其与疫情的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This research aims to analyze the application regularity of Chinese patent medicine during the COVID-19 epidemic by collecting the names of the top three Chinese patent medicines used by 24 hospitals in 14 provinces of China in four time periods (January 20-22, February 16-18, March 01-03, April 01-03, 2020), and explore its contribution to combating the disease. Methods: 1) We built a database of the top three Chinese patent medicines used by 24 hospitals. 2) The frequency and efficacy distribution of Chinese patent medicine were analyzed with risk areas, regions, and hospitals of different properties as three factors. 3) Finally, we analyzed the differences in the use of heat-clearing and non-heat-clearing medicines among the three factors (χ2 test) and the correlation between the Chinese patent medicine and COVID-19 epidemic (correlation analysis) with SPSS 23.0 statistical software. Results: 1) The heat-clearing medicine was the main use category nationwide during January 20-22, 2020. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in different risk areas (p < 0.01). 2) The variety of Chinese patent medicine was increased nationwide during February 16-18, 2020, mainly including tonics, blood-activating and resolving-stasis, and heat-clearing medicines. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in the southern and northern regions (p < 0.05). 3) Tonics, and blood-activating and resolving-stasis medicines became the primary use categories nationwide during March 01-03, 2020. 4) The tonics class, and blood-activating and resolving-stasis medicine were still the primary categories nationwide during April 01-03, 2020. Meanwhile, there was a significant difference in the utilization rate of heat-clearing and non-heat-clearing medicine in different risk areas (p < 0.01). Conclusion: Chinese patent medicine has a certain degree of participation in fighting against the COVID-19. The efficacy distribution is related to the risk area, region, and hospital of different properties, among which the risk area is the main influencing factor. It is hoped that future research can further collect the application amount of Chinese patent medicine used in hospitals all over the country, so as to perfectly reflect the relationship between Chinese patent medicine and the epidemic situation.
引用
- Zhang N, Shi N, Li S, et al. A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China. Front Pharmacol. 2020. PMID: 33776751. doi:10.3389/fphar.2020.574562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。